Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2

2MO - Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC


30 Mar 2022


Mini Oral session 2


Clinical Research

Tumour Site

Non-Small Cell Lung Cancer


Shun Lu


Annals of Oncology (2022) 33 (suppl_2): S27-S70. 10.1016/annonc/annonc856


S. Lu1, J. Fang2, X. Li3, L. Cao4, J. Zhou5, Q. Guo6, Z. Liang7, Y. Cheng8, L. Jiang9, N. Yang10, Z. Han11, J. Shi12, Y. Chen13, H. Xu14, H. Zhang15, G. Chen16, R. Ma17, S. Sun18, Y. Fan19, S. Weiguo20

Author affiliations

  • 1 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai/CN
  • 2 Peking University Cancer Hospital & Institute, Beijing/CN
  • 3 The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN
  • 4 Anhui Provincial Hospital, The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, Hefei/CN
  • 5 The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou/CN
  • 6 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 250000 - Taian/CN
  • 7 West China School of Medicine and West China Hospital, Sichuan University, Chengdu/CN
  • 8 Jilin Cancer Hospital, Changchun/CN
  • 9 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 10 Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha/CN
  • 11 The Affiliated Cancer Hospital of Xinjiang Medical University, Urumuqi/CN
  • 12 Linyi Cancer Hospital, Linyi/CN
  • 13 Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan/CN
  • 14 The Second Affiliated Hospital of Nanchang University, Nanchang/CN
  • 15 Tangdu Hospital, Fourth Military Medical University, Xi'An/CN
  • 16 Affiliated Cancer Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 17 Liaoning Cancer Hospital, Shenyang, Liaoning/CN
  • 18 Xuzhou Central Hospital, Xuzhou/CN
  • 19 Zhejiang Cancer Hospital, Hangzhou/CN
  • 20 HUTCHMED, Shanghai/CN


Login to access the resources on OncologyPRO.

Abstract 2MO


Savolitinib, a highly selective MET tyrosine kinase inhibitor, has shown promising activity and tolerable safety in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other NSCLCs harboring MET exon14 skipping mutations (METex14+) (Lu, 2021). Here we report the long-term overall survival (OS), exposure and subgroup analysis results.


In the open-label phase 2 study, eligible pts received oral savolitinib at 600 mg (body weight ≥50 kg) or 400 mg (<50 kg), QD in 21-day cycles. The primary objectives were OS and treatment exposure with a longer follow up time. Subgroup analysis was performed by prior systemic treatment (yes vs. no), NSCLC subtypes (PSC vs. other NSCLCs) and brain metastases.


Of 70 pts enrolled and assigned to treatment (FAS), 25 were diagnosed as PSC and 45 as other NSCLCs, 28 were treatment-naïve and 42 were pretreated, 15 pts had CNS lesions. The data cutoff for final analysis was Jun 28, 2021. Eight pts are still on-treatment and 14 (20%) pts with more than 18-mo treatment. With a median follow up time of 28.4 mo (IQR 26.2–36.3), the median OS (mOS) was 12.5 mo (95%CI 10.5–21.4) in FAS; 18-mo OS rate, 42.1%; 24-mo OS rate, 31.5%. In pretreated and treatment naïve subgroups, 28.6% (12/42) and 46.4% (13/28) were PSC pts, respectively, and mOS was 19.4 mo (95%CI 10.5-31.3) and 10.9 mo (95%CI 7.5–14.0); 18-mo OS rate, 50.4% and 29.7%; 24-mo OS rate, 37.5% and 22.3%; respectively. In PSC and other NSCLC pts, mOS was 10.6 mo (95%CI 4.6–14.0) and 17.3 mo (95%CI 10.6–23.6); 18-mo OS rate, 29.9% and 49.0%; 24-mo OS rate, 25.6% and 34.7%; respectively. Pts with brain metastases had mOS of 17.7 mo (95%CI 10.48–NA), 18-m OS rate 50.0% and 24-m OS rate 35.7%. Grade ≥3 treatment-related adverse events were reported in 32 (45.7%) pts, the most frequent being AST increased (12.9%), ALT increased (10.0%) and peripheral oedema (8.6%). Overall, with prolonged follow-up and exposure, the incidences of AE were similar to previously reported data, and consistent across subgroups.


The updated results further confirm the favorable benefit of savolitinib in pts with METex14+ NSCLC and each subgroup, and the acceptable safety profile.

Clinical trial identification


Legal entity responsible for the study





S. Weiguo: Other, Personal, Officer: HUTCHMED. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.